

Cancer Targeted Therapy-United States Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/CCCFD9AC2F48EN.html>

Date: May 2018

Pages: 148

Price: US\$ 3,480.00 (Single User License)

ID: CCCFD9AC2F48EN

Abstracts

Report Summary

Cancer Targeted Therapy-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Cancer Targeted Therapy industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole United States and Regional Market Size of Cancer Targeted Therapy 2013-2017, and development forecast 2018-2023

Main market players of Cancer Targeted Therapy in United States, with company and product introduction, position in the Cancer Targeted Therapy market

Market status and development trend of Cancer Targeted Therapy by types and applications

Cost and profit status of Cancer Targeted Therapy, and marketing status

Market growth drivers and challenges

The report segments the United States Cancer Targeted Therapy market as:

United States Cancer Targeted Therapy Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

New England

The Middle Atlantic

The Midwest

The West

The South

Southwest

United States Cancer Targeted Therapy Market: Product Type Segment Analysis
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Tumor Antigens As Targets of Antibodies
Development of Antibodies for Clinical Purposes
Complement Dependent Cytotoxicity (CDC)
Signal Transduction Changes

United States Cancer Targeted Therapy Market: Application Segment Analysis
(Consumption Volume and Market Share 2013-2023; Downstream Customers and
Market Analysis)

Hospital
Clinic
Other

United States Cancer Targeted Therapy Market: Players Segment Analysis (Company
and Product introduction, Cancer Targeted Therapy Sales Volume, Revenue, Price and
Gross Margin):

Advaxis
Bind Therapeutics
Boehringer Ingelheim
Bristol Mayer Squibb
Celldex Therapeutics
Dendreon Corporation
Eli Lilly
GalaxoSmithKline
Galena Biopharma
Genetech
ImmunoCellular Therapeutics
ImmunoGen
Inovio Pharmaceuticals
Johnson & Johnson
NeoStem Oncology
NewLink Genetics
Northwest Biotherapeutics
Merck
Novartis
Peregrine Pharmaceuticals

Pfizer
Roche
Sanofi
Seattle Genetics
Teva

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF CANCER TARGETED THERAPY

- 1.1 Definition of Cancer Targeted Therapy in This Report
- 1.2 Commercial Types of Cancer Targeted Therapy
 - 1.2.1 Tumor Antigens As Targets of Antibodies
 - 1.2.2 Development of Antibodies for Clinical Purposes
 - 1.2.3 Complement Dependent Cytotoxicity (CDC)
 - 1.2.4 Signal Transduction Changes
- 1.3 Downstream Application of Cancer Targeted Therapy
 - 1.3.1 Hospital
 - 1.3.2 Clinic
 - 1.3.3 Other
- 1.4 Development History of Cancer Targeted Therapy
- 1.5 Market Status and Trend of Cancer Targeted Therapy 2013-2023
 - 1.5.1 United States Cancer Targeted Therapy Market Status and Trend 2013-2023
 - 1.5.2 Regional Cancer Targeted Therapy Market Status and Trend 2013-2023

CHAPTER 2 UNITED STATES MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Cancer Targeted Therapy in United States 2013-2017
- 2.2 Consumption Market of Cancer Targeted Therapy in United States by Regions
 - 2.2.1 Consumption Volume of Cancer Targeted Therapy in United States by Regions
 - 2.2.2 Revenue of Cancer Targeted Therapy in United States by Regions
- 2.3 Market Analysis of Cancer Targeted Therapy in United States by Regions
 - 2.3.1 Market Analysis of Cancer Targeted Therapy in New England 2013-2017
 - 2.3.2 Market Analysis of Cancer Targeted Therapy in The Middle Atlantic 2013-2017
 - 2.3.3 Market Analysis of Cancer Targeted Therapy in The Midwest 2013-2017
 - 2.3.4 Market Analysis of Cancer Targeted Therapy in The West 2013-2017
 - 2.3.5 Market Analysis of Cancer Targeted Therapy in The South 2013-2017
 - 2.3.6 Market Analysis of Cancer Targeted Therapy in Southwest 2013-2017
- 2.4 Market Development Forecast of Cancer Targeted Therapy in United States 2018-2023
 - 2.4.1 Market Development Forecast of Cancer Targeted Therapy in United States 2018-2023
 - 2.4.2 Market Development Forecast of Cancer Targeted Therapy by Regions 2018-2023

CHAPTER 3 UNITED STATES MARKET STATUS AND FORECAST BY TYPES

3.1 Whole United States Market Status by Types

3.1.1 Consumption Volume of Cancer Targeted Therapy in United States by Types

3.1.2 Revenue of Cancer Targeted Therapy in United States by Types

3.2 United States Market Status by Types in Major Countries

3.2.1 Market Status by Types in New England

3.2.2 Market Status by Types in The Middle Atlantic

3.2.3 Market Status by Types in The Midwest

3.2.4 Market Status by Types in The West

3.2.5 Market Status by Types in The South

3.2.6 Market Status by Types in Southwest

3.3 Market Forecast of Cancer Targeted Therapy in United States by Types

CHAPTER 4 UNITED STATES MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Cancer Targeted Therapy in United States by Downstream Industry

4.2 Demand Volume of Cancer Targeted Therapy by Downstream Industry in Major Countries

4.2.1 Demand Volume of Cancer Targeted Therapy by Downstream Industry in New England

4.2.2 Demand Volume of Cancer Targeted Therapy by Downstream Industry in The Middle Atlantic

4.2.3 Demand Volume of Cancer Targeted Therapy by Downstream Industry in The Midwest

4.2.4 Demand Volume of Cancer Targeted Therapy by Downstream Industry in The West

4.2.5 Demand Volume of Cancer Targeted Therapy by Downstream Industry in The South

4.2.6 Demand Volume of Cancer Targeted Therapy by Downstream Industry in Southwest

4.3 Market Forecast of Cancer Targeted Therapy in United States by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF CANCER TARGETED THERAPY

5.1 United States Economy Situation and Trend Overview

5.2 Cancer Targeted Therapy Downstream Industry Situation and Trend Overview

CHAPTER 6 CANCER TARGETED THERAPY MARKET COMPETITION STATUS BY MAJOR PLAYERS IN UNITED STATES

6.1 Sales Volume of Cancer Targeted Therapy in United States by Major Players

6.2 Revenue of Cancer Targeted Therapy in United States by Major Players

6.3 Basic Information of Cancer Targeted Therapy by Major Players

6.3.1 Headquarters Location and Established Time of Cancer Targeted Therapy Major Players

6.3.2 Employees and Revenue Level of Cancer Targeted Therapy Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 CANCER TARGETED THERAPY MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Advaxis

7.1.1 Company profile

7.1.2 Representative Cancer Targeted Therapy Product

7.1.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Advaxis

7.2 Bind Therapeutics

7.2.1 Company profile

7.2.2 Representative Cancer Targeted Therapy Product

7.2.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Bind Therapeutics

7.3 Boehringer Ingelheim

7.3.1 Company profile

7.3.2 Representative Cancer Targeted Therapy Product

7.3.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim

7.4 Bristol Mayer Squibb

7.4.1 Company profile

7.4.2 Representative Cancer Targeted Therapy Product

7.4.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Bristol Mayer Squibb

7.5 Celldex Therapeutics

7.5.1 Company profile

7.5.2 Representative Cancer Targeted Therapy Product

7.5.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Celldex Therapeutics

7.6 Dendreon Corporation

7.6.1 Company profile

7.6.2 Representative Cancer Targeted Therapy Product

7.6.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Dendreon Corporation

7.7 Eli Lilly

7.7.1 Company profile

7.7.2 Representative Cancer Targeted Therapy Product

7.7.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Eli Lilly

7.8 GalaxoSmithKline

7.8.1 Company profile

7.8.2 Representative Cancer Targeted Therapy Product

7.8.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of GalaxoSmithKline

7.9 Galena Biopharma

7.9.1 Company profile

7.9.2 Representative Cancer Targeted Therapy Product

7.9.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Galena Biopharma

7.10 Genentech

7.10.1 Company profile

7.10.2 Representative Cancer Targeted Therapy Product

7.10.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Genentech

7.11 ImmunoCellular Therapeutics

7.11.1 Company profile

7.11.2 Representative Cancer Targeted Therapy Product

7.11.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of ImmunoCellular Therapeutics

7.12 ImmunoGen

7.12.1 Company profile

7.12.2 Representative Cancer Targeted Therapy Product

7.12.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of ImmunoGen

7.13 Inovio Pharmaceuticals

7.13.1 Company profile

7.13.2 Representative Cancer Targeted Therapy Product

7.13.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Inovio Pharmaceuticals

7.14 Johnson & Johnson

7.14.1 Company profile

7.14.2 Representative Cancer Targeted Therapy Product

7.14.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Johnson & Johnson

7.15 NeoStem Oncology

7.15.1 Company profile

7.15.2 Representative Cancer Targeted Therapy Product

7.15.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of NeoStem Oncology

7.16 NewLink Genetics

7.17 Northwest Biotherapeutics

7.18 Merck

7.19 Novartis

7.20 Peregrine Pharmaceuticals

7.21 Pfizer

7.22 Roche

7.23 Sanofi

7.24 Seattle Genetics

7.25 Teva

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF CANCER TARGETED THERAPY

8.1 Industry Chain of Cancer Targeted Therapy

8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF CANCER TARGETED THERAPY

9.1 Cost Structure Analysis of Cancer Targeted Therapy

9.2 Raw Materials Cost Analysis of Cancer Targeted Therapy

9.3 Labor Cost Analysis of Cancer Targeted Therapy

9.4 Manufacturing Expenses Analysis of Cancer Targeted Therapy

CHAPTER 10 MARKETING STATUS ANALYSIS OF CANCER TARGETED THERAPY

10.1 Marketing Channel

10.1.1 Direct Marketing

10.1.2 Indirect Marketing

10.1.3 Marketing Channel Development Trend

10.2 Market Positioning

10.2.1 Pricing Strategy

10.2.2 Brand Strategy

10.2.3 Target Client

10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Reference

I would like to order

Product name: Cancer Targeted Therapy-United States Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/CCCFD9AC2F48EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CCCFD9AC2F48EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970